Skip to main content
Premium Trial:

Request an Annual Quote

Scienion Opens US Office to Broaden Arrayer Sales, OEM Services


By Justin Petrone

German array firm Scienion has established a US subsidiary to serve American and Canadian customers, the firm's CEO said this week.

Holger Eickhoff told BioArray News that the new office, located in Princeton, NJ, is "just the start" of the Berlin-based firm's expansion into North America.

While Scienion made its decision to open a US office to meet demand for its arrayer instruments and contract printing services, the move also follows the termination of a deal last month that would have seen Toronto-based SQI Diagnostics acquire Scienion for $15.6 million and enable the combined firm to reach more customers in both North America and Europe (BAN 10/11/2011). Citing market conditions, SQI was unable to raise the funds to complete the transaction.

According to Eickhoff, privately held Scienion's business in the US and Canada has grown to the "right size" to open a subsidiary, and the firm "needed to get closer to customers to support their applications after the SQI deal didn't materialize."

Founded in 2000, Scienion has launched six distinct SciFlexarrayer instruments to date: the entry-level model DW, which can produce four arrays in one run; the S3 for R&D applications; the S5 and S11 for medium-throughput array manufacturing; the S100, which can produce over 1,000 arrays per run for high-throughput manufacturing; and the compact SX system, which includes components from all of Scienion's arrayers in one enclosure.

The company also has a busy original equipment manufacturing services business that has benefitted as arrays are used more frequently in diagnostics, even despite a shift in some markets, such as gene expression, that favor next-generation sequencing.

"Arrays are moving away from high-density research tools towards diagnostics applications, which are clearly supported by Scienion products," said Eickhoff.

According to Eickhoff, Scienion's US subsidiary will initially focus on selling and supporting its menu of arrayers. By the second quarter of 2012, the company hopes to offer contract services that are certified to meet International Organization for Standardization 9001 guidelines covering quality manufacturing systems.

For the past few years, Scienion had been serving the US market via distributors. Eickhoff said that the US market is "very diverse," in terms of customers and applications, and "this is why we need to be in the country directly."

He also said that Scienion will focus on serving North American customers for the time being, and has no planned expansions to Central or South America. Scienion currently maintains distributors in France, Italy, Singapore, Malaysia, Indonesia, South Korea, and Japan.

Craig Cardella, formerly the East Coast sales manager for Spokane, Wash.-based Matrical Bioscience, will direct Scienion's US office. Eickhoff said that he is not yet sure how large a workforce the German company will require to support North American customers. Scienion previously worked with Matrical in 2009, when the firms jointly launched SciSwifter, a microfluidic device for dispensing liquids into microplates (BAN 1/13/2009).

Have topics you'd like to see covered in BioArray News? Contact the editor a1t jpetrone [at] genomeweb [.] com.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.